Enlivex Therapeutics (NASDAQ:ENLV) vs. Surrozen (NASDAQ:SRZN) Head-To-Head Analysis

Enlivex Therapeutics (NASDAQ:ENLV) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Insider & Institutional Ownership

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Enlivex Therapeutics and Surrozen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1	1	1	0	2.00
Surrozen	1	0	3	1	2.80

Enlivex Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 2,742.38%. Surrozen has a consensus price target of $42.00, suggesting a potential upside of 71.29%. Given Enlivex Therapeutics’ higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Surrozen.

Risk and Volatility

Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Earnings & Valuation

This table compares Enlivex Therapeutics and Surrozen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($0.55)	-1.06
Surrozen	$3.48 million	81.80	-$242.03 million	($37.59)	-0.65

Enlivex Therapeutics has higher earnings, but lower revenue than Surrozen. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enlivex Therapeutics and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.